Kelsey Goodwin
Stock Analyst at Piper Sandler
(4.88)
# 53
Out of 5,150 analysts
36
Total ratings
74.19%
Success rate
54.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Downgrades: Neutral | $120 → $115 | $114.30 | +0.61% | 4 | Feb 26, 2026 | |
| RVMD Revolution Medicines | Maintains: Overweight | $75 → $120 | $101.19 | +18.59% | 2 | Feb 26, 2026 | |
| TNGX Tango Therapeutics | Maintains: Overweight | $11 → $14 | $12.35 | +13.36% | 2 | Jan 16, 2026 | |
| JANX Janux Therapeutics | Maintains: Overweight | $42 → $30 | $14.35 | +109.06% | 2 | Jan 16, 2026 | |
| ERAS Erasca | Maintains: Overweight | $5 → $11 | $15.12 | -27.25% | 2 | Jan 16, 2026 | |
| CGON CG Oncology | Maintains: Overweight | $55 → $70 | $61.57 | +13.69% | 2 | Jan 16, 2026 | |
| BDTX Black Diamond Therapeutics | Maintains: Overweight | $9 → $8 | $2.46 | +225.20% | 2 | Jan 16, 2026 | |
| TARA Protara Therapeutics | Initiates: Overweight | $24 | $6.20 | +287.10% | 1 | Jan 7, 2026 | |
| ORIC ORIC Pharmaceuticals | Initiates: Overweight | $22 | $13.51 | +62.84% | 1 | Jan 7, 2026 | |
| DAWN Day One Biopharmaceuticals | Maintains: Overweight | $25 → $26 | $12.87 | +102.02% | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $128 | $102.67 | +24.67% | 4 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $21 | $15.38 | +36.54% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $20.16 | +78.57% | 4 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $18.54 | +94.17% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $2.43 | - | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.68 | +198.51% | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.08 | - | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $17.85 | - | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $4.26 | - | 1 | Oct 31, 2022 |
Arcellx
Feb 26, 2026
Downgrades: Neutral
Price Target: $120 → $115
Current: $114.30
Upside: +0.61%
Revolution Medicines
Feb 26, 2026
Maintains: Overweight
Price Target: $75 → $120
Current: $101.19
Upside: +18.59%
Tango Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $11 → $14
Current: $12.35
Upside: +13.36%
Janux Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $42 → $30
Current: $14.35
Upside: +109.06%
Erasca
Jan 16, 2026
Maintains: Overweight
Price Target: $5 → $11
Current: $15.12
Upside: -27.25%
CG Oncology
Jan 16, 2026
Maintains: Overweight
Price Target: $55 → $70
Current: $61.57
Upside: +13.69%
Black Diamond Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $9 → $8
Current: $2.46
Upside: +225.20%
Protara Therapeutics
Jan 7, 2026
Initiates: Overweight
Price Target: $24
Current: $6.20
Upside: +287.10%
ORIC Pharmaceuticals
Jan 7, 2026
Initiates: Overweight
Price Target: $22
Current: $13.51
Upside: +62.84%
Day One Biopharmaceuticals
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $26
Current: $12.87
Upside: +102.02%
Oct 27, 2025
Maintains: Overweight
Price Target: $112 → $128
Current: $102.67
Upside: +24.67%
Aug 19, 2025
Initiates: Neutral
Price Target: $21
Current: $15.38
Upside: +36.54%
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $20.16
Upside: +78.57%
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $18.54
Upside: +94.17%
Mar 28, 2025
Reiterates: Buy
Price Target: n/a
Current: $2.43
Upside: -
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $2.68
Upside: +198.51%
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.08
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $17.85
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $4.26
Upside: -